← All trials
NCT05021016
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 19, 2020
- Primary completion
- Jan 30, 2021
- Completion date
- Jan 30, 2021
- First posted
- Aug 25, 2021
- Last posted
- Aug 27, 2021
- Enrollment
- 150
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of RussiaLead sponsor
- Burnasyan Federal Medical Biophysical CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.